Strategic Overview
FY23 advanced clinical validation and global engagement in antimicrobial research. Focus intensified on reducing nephrotoxicity in critical antibiotics while strengthening regulatory presence worldwide.
Development Milestones
- VRP-034 pre-clinical development completed
- Scientific advice sought from the UK MHRA
- Demonstrated reduced polymyxin B-associated nephrotoxicity
- Maintained therapeutic efficacy
- Renal Guard patent filed in 85+ countries
- The kidney-on-a-chip lab was installed
The operational kidney-on-a-chip lab enabled deeper toxicity mechanism research and laid the groundwork for future multi-organ systems.
Regulatory Achievements
- 138 product approvals received
- Approvals across 40+ countries
- 30 products commercially rolled out
Scientific Recognition & Publications
- VRP-034 results presented at European and American microbiology conferences
- Enoxaparin clinical study published in Pharmacology Research & Perspectives
- Invited speaker at Indo-German AMR workshop (Berlin)
- Participation in India AMR Innovation Hub advisory council
Global Validation
The World Health Organization’s Antibacterial Pipeline Review for 2021 identifies 10 preclinical candidates in the development pipeline from India, with 5 of them originating from VMRC
FY23 reinforced global scientific credibility and leadership in antimicrobial resistance research.